Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk (TIERRA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00874185
First received: April 1, 2009
Last updated: February 12, 2013
Last verified: February 2013
  Purpose

Evaluate satisfaction in people treated with IPDE5 inhibitors over time


Condition Phase
Erectile Dysfunction
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • EDITS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • SEAR [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Medication prescribed [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 720
Study Start Date: December 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Questionnaire
filling in questionnaires

Detailed Description:

12 first patients that are eligible

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

People with cv risk

Criteria

Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00874185

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00874185     History of Changes
Other Study ID Numbers: A1481256, A1481256
Study First Received: April 1, 2009
Last Updated: February 12, 2013
Health Authority: Spain: Ethics Committee

Keywords provided by Pfizer:
satisfaction

Additional relevant MeSH terms:
Erectile Dysfunction
Genital Diseases, Male
Mental Disorders
Sexual and Gender Disorders
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Phosphodiesterase 5 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors

ClinicalTrials.gov processed this record on October 29, 2014